Abstract
Evinacumab is a monoclonal antibody approved for adjunctive therapy for patients aged 5 years and older with homozygous familial hypercholesterolemia whose low-density lipoprotein (LDL) cholesterol remains elevated despite traditional interventions. Evinacumab is an angiopoietin-like protein 3 (ANGPTL3) inhibitor administered via intravenous infusion. This activity reviews the indications, mechanism of action, adverse reactions, contraindications, and toxicities of evinacumab and highlights the role of the interprofessional team in caring for patients with homozygous familial hypercholesterolemia and related conditions.
| Original language | English |
|---|---|
| Publisher | StatPearls Publishing |
| State | Published - Dec 2023 |